Rinvoq (upadacitinib) Receives U.S. FDA Approval for Active Psoriatic Arthritis

NORTH CHICAGO, Ill., Dec. 14, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved Rinvoq® (upadacitinib; 15 mg, once daily) for the treatment of adults with active psoriatic...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news